Category Archives: Cancer

Medical Information Facilitated by Oncotarget

Recently, Oncotarget reviewed the various oxidation pathway elements that take part in the development of cancer. provided an informative abstract detailing the items that contribute to the growth of cancerous cells causing cancer ailments. They stated that oxidative stress is due to the reactive nitrogen species not balancing with the reactive oxygen species commonly known as (ROS). In the previous decades, Oncotarget’s extensive study indicated that cancer could easily be initiated and formed due to oxidative stress. Not only does oxidation stress begin the development of cancer but also leads to the damage of molecular tissues as well as reduction-oxidation disruption. According to their search on the ISI Science Web, Oncotarget found three categories of listed pathways that contribute to cancer formation and what Oncotarget knows.

Oncotarget’s popularity is attached to Mikhail Blagosklonny, cancer, and aging scientist. Previously, Mikhail served at the Cancer Institute at Roswell Park as its oncology professor. Additionally, Mikhail’s expertise at Oncotarget is attributed to his educational and career experience. He attended the University of St. Petersburg, the medical branch where he attained his cardiology and experimental medicine Ph.D. He then served as an associate medical professor at the New York Medical Institution for several years before joining Oncotarget. His research interests are fascinating as they are directed towards cancer disease. Additionally, Mikhail Blogosklonny focuses his research on specific cancer therapies that engage in the protection of healthy cells from any damage as well as aging mechanisms in biogerontology and more information click here.

Mikhail’s editorial operations rotate around various companies including Oncotarget. Its weekly reviews are based on different research aspects detailing oncology information. Oncotarget was founded in 2010 and is published and supported by Impact Journals. Also, its indexing is performed by prestigious groups including BIOSIS Previews, Science Citation Index Expanded and Index Medicus. Oncotarget’s impact has overtime been rated by the Journal Citation Report which indicated that its impact factor as of 2016 was at 5.168. At Oncotarget, quality reviews regarding cancer augmentation and initiation are provided. Its success is tied to Mikhail, Oncotarget’s chief-editor, which ensures that author offers gratuitous references to other latest papers for their readers. Oncotarget’s mission will be realized under the guidance of diligent personnel like Mikhail Blogosklonny and Oncotarget’s lacrosse camp.

More Visit:

Under leadership of Clay Siegall, Seattle Genetics follows plan of wide diversification

A recurring problem for tech startups has been the inability to successfully diversify the revenue streams into a wide range of business lines. Even some of the most well-known companies that have been started in the last 20 years suffer dramatically from this problem. Firm such as Google and Facebook, even though they have many different product lines, have found it almost impossible to successfully enter into profitable businesses aside from their core business lines.

This is a potentially catastrophic problem for any company, especially one that relies on a new technology that may still be vulnerable to outside competition or attacks from those who may be able to innovate a disruptive solution. As true as this is for tech startups, it is also true in the biotech space. Many biotech firms have been unable to successfully broaden their horizons, becoming almost completely dependent on one narrow line of products for their livelihood. This is never an ideal situation and opens up the business to the potential for a catastrophic disruption in their own market.

But one of the biotech’s most innovative CEOs, Clay Siegall, has largely solved this problem for his own company. Seattle Genetics has been successful in widely diversifying its product line into a large array of disparate businesses. Although Seattle Genetics’ core business is its line of antibody drug conjugate products, drugs like ADCetris only make up a relatively small amount of its total revenues.

The firm currently makes a large amount of money from licensing intellectual property to other firms who are developing their own antibody drug conjugates. It also makes a large amount of money on patented processes involved in not just the creation of antibody drug conjugates but many other types of drugs.

One example of this is the firm’s innovative means of developing monoclonal antibodies, which uses laboratory mice to create the basis of synthetic human antibodies. This highly innovative process is the product of Dr. Siegall and has won him worldwide recognition as being one of the most important contributions to targeted cancer therapy that has ever taken place.

Today, it is widely used in the synthesis of monoclonal antibodies.


Cancer Treatment Centers of America Are Finding New Ways to Recognize Individual Differences

Cancer Treatment Centers of America is working on a number of different research projects. However, they recently announced an important milestone in the development of medical technologies. They’ve converged multiple important software platforms into a singular whole called NantOS. This is an impressive diagnostic tool which is expected to be invaluable for medical care as it moves forward. It can best be understood as a way to combine multiple sources of information into a tool focused on individual care.

It’s an important step forward which fits perfectly into the overall treatment methodology of Cancer Treatment Centers of America. Right from the start, they’ve been focused on the idea that complex systems need equally expansive solutions. To begin with, a patient isn’t simply left adrift in the vast ocean of medical information. Care managers are assigned to every patient in order to help them feel comfortable with their treatment strategy. This individual attention continues right into the treatment phase as well.

When Cancer Treatment Centers of America accepts a patient they’re introduced to a whole multidisciplinary team of experts. This is part of a treatment strategy that looks at the entirety of a person’s health rather than just a single aspect of it. The attention to individual care even shows itself in their research projects. The Cancer Treatment Centers of America aren’t just breaking new grounds with medical technology. They’re also involved with cutting edge research such as the TAPUR study. This study looks at ways in which individual differences in patients and cancer can impact standard treatment methods.

This attention to every part of a patient’s health even extends to how side effects are managed. Cancer Treatment Centers of America offer innovative integrative care that can help patients focus on boosting their energy and health even in the midst of an ongoing cancer treatment plan.

Tempus Founder Seeks to Make Data Driven Cancer Treatment

In the Tech News Spy article, “Tempus, Eric Lefkofsky, and the Rise of Data-Enabled Precision Medicine” Heidi Harris discusses the serial entrepreneur’s goals for his new company.

The article begins with several frightening statistics. 40% of American adults will be diagnosed with cancer at some point in their lives. By 2024, the National Cancer Institute expects close to 19 million citizens to be diagnosed with cancer.

Many, including Eric Lefkofsky, originally believed that the healthcare industry using the latest technology to drive more accurate treatments. However, when his wife was diagnosed with breast cancer, Mr. Lefkofsky discovered an uncomfortable truth. Despite having updates like electronic health records, the health industry did not have adequate data collection and digital technology despite the abundance of information being produced.

Data centering on the patients and the treatments may be abundant, but there was never a method to actually make use of the information. Tempus seeks to remedy that. It seeks to create a paradigm shift in cancer treatment by developing a digital library and platform. This platform will interpret the personal molecular data of the patient as well as the clinical information to provide individualized cancer treatment to each patient.

The company had several roadblocks along the way such as discovering accessible and affordable molecular, medical, and clinical data. Not to mention it also had to reorganize physicians notes to obtain the information. The company solved the issue by developing a software with machine learning, including language processing and character recognition abilities. The notes could then be transformed into data that could be applied to the treatment and care of cancer patients.

The company also uses human genome sequencing to fight the disease on the cellular and molecular level. The clinical information combined with the molecular information creates a personalized treatment plan. As the company gains more and more information, it will be able to provide a more precise medicine.

Eric Lefkofsky began the Tempus journey after discovering the issue when his wife was diagnosed. He co-founded the company in 2016. However, it is not his first journey in the entrepreneurial world. He co-founded several companies such as InnerWorkings, Echo Global Logistics, Mediaocean, and Groupon.

However, he is also a dedicated philanthropist. He began the Lefkofsky Foundation with his wife in 2006 to support educational and scientific organizations around the world. He also joined The Giving Pledge in 2013.